Parksmart0114

BACKGROUND Neurological complications are common complications encountered by patients with Left Ventricular Assist Devices (LVAD). OBJECTIVE This single center retrospective study aims to identify the incidence and risk factors of neurological complications and interventions in patients supported with LVADs, and define the associated anticoagulation management. METHODS Between August 2009 and August 2017, 244 patients underwent LVAD implantation. 21 patients were excluded for having neurological complications prior to LVAD placement or for having previously undergone heart transplantation. RESULTS Fifty-six patients (25%) suffered 61 complications, and 11 (19.6%) died as a result. Gender, type of LVAD, or chronic medical comorbidities evaluated did not contribute to a difference in complication rate; in contrast, length of LVAD implantation was directly related to risk of neurological complication. Eleven patients (19.6%) underwent 13 surgical interventions, including five mechanical thrombectomies. Anticoagulation was reversed in 16 patients and held without complication. Anticoagulation was not held for ischemic complications and no clinically significant hemorrhagic transformation occurred. Intravenous Tissue plasminogen activator (TPA) was also successfully administered to 3 patients without complication. CONCLUSION Neurologic complications were observed in 25% of patients supported with LVADs, of which 20% required neurosurgical intervention. Anticoagulation can be safely withheld in patients with hemorrhagic complications. Patients with ischemic complications can continue to be anticoagulated with no significant risk of hemorrhagic transformation. Length of LVAD implantation was directly related to risk of neurological complication. Finally, our study adds to existing literature that mechanical thrombectomy and even IV TPA are options for LVAD patients with ischemic complications. In order to determine the level of cell damage in cancerous cells, current cytogenetic tests have limitations such as time consumption and high cost. The aim of this study was to demonstrate the ability of nonlinear refractive (NLR) index as a predictor of breast cell damage caused by magneto-plasmonic nanoparticle based thermo-radiotherapy treatments. MCF-7 breast cancer cells were subjected individually to the treatment of radiation, radio-frequency (RF) hyperthermia, and radiation + RF hyperthermia. These treatments were repeated in the presence of magneto-plasmonic nanoparticle (Au@IONP). The MTT and nonlinear optical assays were used to evaluate the damage induced by different treatment modalities. The results of MTT were correlated with Z-scan, as the magnitude of nonlinear refraction increased with higher intensity of induced cell damages. In this regard, the lowest cell viability (38%,) and highest magnitude of NLR index (+28.12) were obtained from combination of radiation (at 4 Gy dose) and hyperthermia treatment in the presence of nanoparticles. The proposed optical index (NLR) indicated high capability and can be used as an auxiliary tool to monitor induced cell damage during different treatment strategies. This technique is fast, noninvasive, does not impose cost, and finally does not waste materials. V.Photodynamic therapy (PDT) became an important tool for the treatment of various cutaneous malignant and non-malignant diseases. This therapy involves the application of a photosensitizer to the affected area which is followed by illumination with the light of a particular wavelength resulting in the death of cancerous cells. This review encompasses a brief description of the mechanism of photodynamic therapy and different photosensitizers used clinically. However, the major obstacle with a majority of photosensitizers is its limited bioavailability and long-term photosensitivity which limits its use. To overcome these limitations different nanocarriers systems has been developed and studied for their efficacy in PDT, which forms the focal point of the review. V.Bowen's disease, also named squamous cell carcinoma in situ, is usually treated by surgical excision. However, surgery could cause scars and influence joint function. It is also not suitable to patients with large area of lesions or multiple lesions. Photodynamic therapy (PDT) has advantages of efficacy, safety, without scars or damage to joint function. Selleckchem Adagrasib It could be used repeatedly. Therefore, PDT might be recommended to treat multiple Bowen's disease. This report shared a case of a patient having suffered from multiple Bowen's disease for several times and successfully treated by PDT. PDT not only avoided scars and joint dysfunction, but also raised quality of the patient's daily life. V.Photodynamic therapy (PDT) is currently one of the cancer treatment options. PDT requires the application of a photosensitizer (such as porphyrins, chlorines, and phthalocyanines) that selectively targets malignant cells. It is a big dilemma to find a proper photosensitizer. In our study, we have tested a new in-vitro group of cyanine dyes. These dyes are widely applied in biotechnology as fluorescent markers. Two malignant adenocarcinoma cell lines (MCF-7/WT and MCF-7/DOX) were investigated using photodynamic reaction (PDR) with four cyanine dyes (KF-570, HM-118, FBF-749, and ER-139). KF-570 and HM-118 were irradiated with red light (630 nm), whereas FBF-749 and ER-139 with green light (435 nm). To evaluate PDR efficiency, a clonogenic test was conducted. Apoptosis was investigated by TUNEL and NCA (neutral comet) assays. Proteins selected as indicators of the apoptotic pathway (AIF, sPLA2, Smac/Diablo) and intracellular response markers (SOD-1 and GST-pi) were detected using western blot. The highest number of apoptotic cells (ca. 100%) was observed after PDR with HM-118 and KF-570 in both conducted tests, in both cell lines. The results showed that HM-118 and KF-570 cyanine dyes demonstrated a major phototoxic effect causing apoptosis in doxorubicin-resistant and sensitive cell lines. V.Stabilization of dental implants by means of biomaterials such as bioceramic granules and cements is currently compromised by the poor mechanical properties of these bioceramics. Recently, our group developed a calcium phosphate cement reinforced with poly(vinyl alcohol) fibers with improved flexural strength and toughness. Herein we evaluated the capacity of these fiber-reinforced calcium phosphate cements to stabilize dental implants in vitro and in vivo using a range of mechanical and biological test methods. In vitro, filling of circumferential crestal peri-implant bone defects with synthetic bone analogues with fiber-reinforced calcium phosphate cement demonstrated superior implant stability as compared to fiber-free calcium phosphate cement over a 12-week period. Similarly, filling of circumferential crestal peri-implant bone defects with fiber-reinforced calcium phosphate cement effectively stabilized dental implants installed in a rabbit femoral condyle defect as assessed via both implant stability quotient (ISQ) and torque-out measurements.